North America Liver Cancer Diagnostics Market SWOT Analysis, Size, Share, Trends, Growth and Forecast from 2022 to 2028
The liver cancer
diagnostics market in North America is expected to grow from US$ 3,843.93
million in 2021 to US$ 6,666.24 million by 2028. It is estimated to grow at a CAGR
of 8.2% from 2021 to 2028.
North America Liver
Cancer Diagnostics Market The ability to accurately diagnose liver cancer
progression is critical for selecting the appropriate treatment option.
Further, various companies and organizations have taken enormous initiatives to
develop and implement innovative solutions for the early identification of this
disease in response to the rising demand. For instance, in March 2020, Roche
Holding AG's Elecsys GALAD score received the US Food and Drug Administration's
breakthrough device status for the early detection of an advanced form of liver
cancer. North America Liver Cancer Diagnostics Market The Swiss drugmaker's
calculator combines factors including age, gender, and biomarker results to
detect early-stage hepatocellular carcinoma, which is the most common form of
liver cancer. Further, Elecsys GALAD score is designed to support clinicians by
providing them with a timely and accurate diagnosis of hepatocellular
carcinoma.
North
America Liver Cancer Diagnostics Market
North America Liver Cancer Diagnostics Market Liver cancer,
particularly hepatocellular carcinoma (HCC), is one of the leading causes of
cancer-related mortality worldwide. The increasing prevalence of liver disease,
particularly due to rising rates of chronic hepatitis B and C infections,
alcohol-related liver disease, and non-alcoholic fatty liver disease (NAFLD),
has led to an increase in the number of liver cancer cases. In North America,
the growing demand for effective and early diagnostic tools to detect liver
cancer has fostered the expansion of the liver cancer diagnostics market.This
article will examine the factors driving the growth of the North American liver
cancer diagnostics market, key diagnostic methods, market challenges, and
future prospects in the region.
📚 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝
𝐒𝐚𝐦𝐩𝐥𝐞
𝐏𝐃𝐅
𝐂𝐨𝐩𝐲@
https://www.businessmarketinsights.com/sample/BMIRE00025043
North America Liver Cancer Diagnostics Market The research
and development (R&D) expenditure in 2021 was US$ 14.65 billion, and in
2020, it was US$ 13.17 billion. The research and development (R&D)
expenditure grew by 14% on a core basis in F. Hoffmann-La Roche Ltd., North
America Liver Cancer Diagnostics Market mostly driven by late-stage investments
in oncology, ophthalmology, and personalized healthcare. In 2021, the R&D
investment in the diagnostic division was US$ 1,878.92 million. Similarly, In
November 2019, EXACT Sciences Corporation received the Food and Drug
Administration's (FDA) breakthrough designation for its blood-based test for
early detection of liver cancer.Additionally, in June 2020, National Institutes
of Health (NIH) scientists developed blood tests to help improve liver cancer
screening, led by researchers at the National Cancer Institute (NCI). In
addition, in June 2019, CancerSEEK, a liquid biopsy test, was designed by
researchers at Johns Hopkins University. North America Liver Cancer Diagnostics
Market The test was designed to diagnose multiple cancers, including stomach,
liver, ovarian, and esophageal, at an early stage, facilitating early
treatment. Therefore, the increasing R&D investments and development of
diagnostic tests for the detection of liver cancer are driving the liver cancer
diagnostics market.
With new features and technologies, vendors can attract new
customers and expand their footprints in emerging markets. This factor is
likely to drive the North America Liver cancer diagnostics market at a
substantial CAGR during the forecast period.
𝐓𝐡𝐞 𝐋𝐢𝐬𝐭
𝐨𝐟
𝐂𝐨𝐦𝐩𝐚𝐧𝐢𝐞𝐬
Abbott
bioMerieux SA
F. HOFFMANN-LA ROCHE LTD.
Illumina, Inc.
Koninklijke Philips N.V.
QIAGEN
Siemens Healthineers AG
THERMO FISHER SCIENTIFIC INC.
GE Healthcare
Perspectum
📚𝐅𝐮𝐥𝐥
𝐑𝐞𝐩𝐨𝐫𝐭
𝐋𝐢𝐧𝐤
@ https://www.businessmarketinsights.com/reports/north-america-liver-cancer-diagnostics-market
Drivers of
Market Growth
Several factors are contributing to the expansion of the
liver cancer diagnostics market in North America:
1.Rising Incidence of Liver Cancer: North America Liver
Cancer Diagnostics Market The number of liver cancer cases in North America has
been steadily increasing, driven by the growing incidence of risk factors like
chronic hepatitis infections, alcohol abuse, and NAFLD. The Centers for Disease
Control and Prevention (CDC) has reported a significant rise in the rates of
liver cancer in the United States in recent years, underscoring the urgent need
for improved diagnostic tools.
2.Technological Advancements in Diagnostic Tools: North
America Liver Cancer Diagnostics Market The development of advanced imaging
technologies such as contrast-enhanced ultrasound (CEUS), elastography, and
molecular diagnostic tests has made early detection of liver cancer more
accurate and accessible. The increasing adoption of non-invasive diagnostic
technologies such as liquid biopsy and blood-based biomarker assays has also
contributed to the market’s growth.
3.Government Initiatives and Awareness Campaigns: North
America Liver Cancer Diagnostics Market Governments and health organizations
are investing in liver cancer awareness and screening programs, aiming to
detect liver cancer in its early stages when treatment options are more
effective. This has spurred the demand for liver cancer diagnostic services,
driving market growth.
4.Improved Healthcare Infrastructure: North America Liver
Cancer Diagnostics Market The availability of state-of-the-art healthcare
facilities, especially in urban areas across the United States and Canada, has
increased the accessibility of diagnostic tests. The growing number of
specialized cancer centers is contributing to the rise in diagnostic
procedures.
5.Aging Population: North America Liver Cancer Diagnostics
Market North America has an aging population, and with age being one of the
major risk factors for liver cancer, the incidence of liver cancer is expected
to rise. This demographic trend is expected to drive the demand for liver
cancer diagnostic services, as older individuals are more likely to develop
liver disease and cancer.
Market
Overview
Liver cancer diagnostics include
various methods to detect, stage, and evaluate liver cancer. These diagnostic
tests are critical in providing timely and accurate diagnosis, which is
essential for deciding the appropriate treatment options. The market for liver
cancer diagnostics in North America is expected to experience robust growth due
to advancements in diagnostic technologies, increased awareness of liver
cancer, and the high burden of liver-related diseases in the region.
The diagnostic methods used for
liver cancer include imaging techniques, biomarker tests, and liver biopsy.
Imaging techniques such as ultrasound, computed tomography (CT), and magnetic
resonance imaging (MRI) are widely used for liver cancer detection. Biomarker
tests, including serum biomarkers like alpha-fetoprotein (AFP), are also
important in diagnosing liver cancer. In some cases, a biopsy may be performed
to confirm the diagnosis and determine the cancer’s stage.
Key
Diagnostic Methods
Several diagnostic tools are used to
diagnose liver cancer, and the market for these methods is expected to grow
with advancements in technology and increased healthcare investment. Key
diagnostic methods include:
1.
Imaging Techniques
- Ultrasound:
Ultrasound is often the first imaging technique used to detect liver
cancer. It is non-invasive, inexpensive, and widely available, making it
an essential tool in the diagnostic process.
- CT Scan:
A computed tomography (CT) scan is more detailed than ultrasound and can
help identify liver tumors and assess their size and location. It is often
used in conjunction with other tests for accurate diagnosis and staging.
- MRI:
Magnetic resonance imaging (MRI) is more precise than CT for detecting
liver cancer. It is particularly useful in identifying smaller tumors and
assessing the liver's functional characteristics. MRI is also used to
monitor the progress of cancer treatments.
2.
Biomarkers and Blood Tests
- Alpha-fetoprotein (AFP): AFP is a protein often elevated in liver cancer
patients. A blood test to measure AFP levels can provide important
information for diagnosing liver cancer, though it is not always reliable
as a sole diagnostic marker.
- Other Biomarkers:
In addition to AFP, several other biomarkers, such as des-gamma-carboxy
prothrombin (DCP) and glypican-3, have shown promise in diagnosing liver
cancer. These biomarkers can be used in combination to increase diagnostic
accuracy.
𝐀𝐛𝐨𝐮𝐭 𝐔𝐬:
Business
Market Insights is a market research platform that provides subscription
service for industry and company reports. Our research team has extensive
professional expertise in domains such as Electronics & Semiconductor;
Aerospace & Defense; Automotive & Transportation; Energy & Power;
Healthcare; Manufacturing & Construction; Food & Beverages; Chemicals
& Materials; and Technology, Media, & Telecommunications.
You can see this-
North America
Liquid Biopsy Market- https://postyourarticle.com/north-america-liquid-biopsy-market-identifying-roles-and-objectives-in-coming-years-till-2027/
North America Healthcare Contract Research
Organizations (CRO) Services Market- https://www.globalpostnews.com/uncategorized/north-america-healthcare-contract-research-organizations-cro-services-market-size-growth-status-analysis-and-forecast-2027/
North
America Railway Cyber Security Market- https://www.openpr.com/news/3929498/north-america-coffee-beans-market-regional-share-global-size
North America Acetonitrile Market- https://businessmarketreportsblog.wordpress.com/2025/03/21/north-america-acetonitrile-market-size-growth-status-analysis-and-forecast-2027/
Comments
Post a Comment